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Aim: To compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Materials and Methods: Gleason 
score and age at diagnosis of familial group and sporadic group were compared by χ2 and t-test. Cancer-specific survival rates were 
analyzed by the Kaplan — Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05. Results: 
Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) 
patients. The familial group patient’s mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8–60.1) was signifi-
cantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7–67.6) (p < 0.0001). Comparing Gleason score 
between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% 
CI 0.88–0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than 
that of sporadic group with 69% (95% CI 0.60–0.78) 10-year cancer-specific survival rates (p = 0.0237). Conclusion: The study data 
demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific sur-
vival rates, but not Gleason score.
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Prostate cancer (PC) is considered to be one 
of the most challenging problems in oncology today. 
The developed Western countries have seen an in-
crease in the PC incidence overtaking now the inci-
dence of lung cancer thus becoming an absolute lea-
der, with lung cancer, however, still leading in terms 
of mortality [1]. Although not all causes triggering 
PC have been identified yet, age, race and heredity 
prove to be obvious risk factors. According to research 
data PC risk doubles in case one of the first degree 
relatives suffers from it. The said risk will increase 
by 5–11 times with two or more first degree relatives 
being PC diagnosed [2, 3]. Up to 9% of all PC cases 
fall on hereditary PC (HPC), which tends to develop 
6–7 years earlier than sporadic PC (SPC) [3].
For other malignancies the heredity factor im-
pacts prognosis. Thus, triple-negative breast cancer 
(TNBC) BRCA1 mutation carriers tend to respond 
better to chemotherapy and have better survival rates 
than sporadic TNBC [4, 5]. Overall survival in case 
of the Lynch syndrome is better than for sporadic 
colorectal cancer patients [6, 7]. However, this is not 
true for all localizations: e.g., patients with hereditary 
endometrial cancer have lower survival rates than 
the sporadic endometrial cancer group [8]. The aim 
of the present study was to compare cancer-specific 
survival (CSS) rates for familial PC (FPC) and SPC.
MATERIALS AND METHODS
Study groups. Pauls Stradins University Hospital 
outpatient clinic provides medical services to about 
⅓ of all PC patients in Latvia. As many as 4136 PC pa-
tients at all stages of the disease received treatment 
at the clinic from April 2000 to November 2012. There 
were 1175 PC patients corresponding to inclusion/
exclusion criteria involved in the study. Inclusion cri-
teria were as follows: histologically verified PC; signed 
informed consent forms. Exclusion criteria: other onco-
logical diseases; lack of family medical history; mental 
state of patients preventing them from understanding 
the essence of the research. The follow-up observation 
period lasted till February 2013. Gleason score was 
available for 622 patients. The study was approved 
by the P. Stradins University Hospital Ethics Committee.
HPC cases were defined as such according to Johns 
Hopkins criteria: at least 3 PC cases among first degree 
relatives, or PC in three consecutive generations of ma-
ternal/paternal lineages, or at least 2 blood relatives 
under 55 developing PC [9]. FPC cases were defined 
as such when there were 2 PC cases among first degree 
relatives, or one PC case in one relative under 55.
Statistical methods. Gleason score of the familial 
group (FG) and the sporadic group (SG) were analyzed 
by χ2-test, and age at diagnosis of FG and SG were 
compared by t-test. CSS rates were analyzed by the 
Kaplan — Meier method and compared by log-rank test. 
Statistically significant level set at p < 0.05. All statistical 
analysis was performed using R software version 3.0.3.
RESULTS
There were 12 definitive HPC cases and 203 FPC 
ones among 1175 PC patients. Taking into account 
the small number of definitive HPC patients both 
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groups were combined, thus constituting one 
FG of 215 (18.3% of all patients). The SG consisted 
of 960 (81.7%) patients. The FG patient’s mean age 
at diagnosis (58.9 years old, 95% confidence inter-
val (CI) 57.8–60.1) was significantly lower than that 
of SG patient’s (67.2 years old, 95% CI 66.7–67.6) 
(p < 0.0001). Comparing Gleason score between 
FG and SG revealed no statistically significant diffe-
rence (Table). The analysis showed that 92% (95% 
CI 0.88–0.97) of FG patients had a 10-year CSS, which 
was a significantly better outcome than that of SG with 
69% (95% CI 0.60–0.78) 10-year CSS (p = 0.0237) 
(Figure).
Table. Clinical characteristics of FG and SG patients
Characteristic of patients FG, n (%) SG, n (%) p-value
All patients, n = 1175 (100%) 215 (18.3) 960 (81.7)
Age at diagnosis, years
Mean 58.9 
(95% CI 57.8–60.1)
67.2 
(95% CI 66.7–67.6)
<0.0001
Age variation 28–85 46–92
Gleason score 0.712
Patients with known Glea-
son score, n = 622 (100%)
130 (20.9) 492 (79.1)
1–4 12 (9.2) 57 (11.6)
5–7 97 (74.6) 352 (71.5)
8–10 21 (16.2) 83 (16.9)
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Figure. CSS rates of FG and SG PC patients
DISCUSSION
Out of the total of 1175 patients participating 
in the study 12 (1.02%) were diagnozed with definitive 
HPC. Some other research data indicate that HPC ratio 
among all PC cases reaches 9–10% [3]. This ratio differ-
ence may be explained by the fact that Latvian families 
are relatively small with the total fertility rate in the coun-
try being 1.22–1.59 over the 2000–2012 period. Due 
to the small size of Latvian families it is often difficult 
to make well-grounded conclusions  concerning heredi-
tary diseases on the basis of the available data on family 
medical history [10]. No statistically significant differ-
ence of Gleason score between FG and SG patients 
was found, which shows that the diffe rence in CSS 
between both groups is not associated with the can-
cer grade. The 10-year PC CSS in Latvia over 1990–
2001 period grew from 32.9% (29.2–36.6) to 40.5% 
(37.2–43.8) [11]. According to our results, the 10-year 
CSS for SG increased to 69%. As far as the 10-year 
CSS for the FG is concerned, it is by 23% higher than 
in the case of SG. Such high CSS rates are shown 
in a Swedish study on PC natural history [12].
In conclusion, the study data demonstrate 
statis tically significant difference between FG and 
SG  regarding age and CSS, but no such difference 
is observed in case of Gleason score.
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